Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone

Journal of Experimental Medicine

Volumn 183, Issue 3, 1996, Pages 927-936

  Bianchi, Marina ^b   Bloom, Ona ^a   Raabe, Tobias ^b   Cohen, Pamela S ^a,b   Chesney, Jason ^b   Sherry, Barbara ^b   Schmidtmayerova, Helena ^b   Calandra, Thierry ^b   Zhang, Xini ^b   Bukrinsky, Michael ^b   Ulrich, Peter ^b   Cerami, Anthony ^b   Tracey, Kevin J ^a,b  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^b PICOWER INST FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDINOHYDRAZONE; ANTIINFLAMMATORY AGENT; CARRAGEENAN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; N,N' BIS(3,5 DIACETYLPHENYL)DECANEDIAMIDE TETRAKIS(AMIDINOHYDRAZONE); NITRIC OXIDE; SEMAPIMOD; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; DRUG EFFICACY; DRUG MECHANISM; DRUG SPECIFICITY; ENDOTOXEMIA; IMMUNOSUPPRESSIVE TREATMENT; MACROPHAGE MIGRATION INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CELL LINE; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INDUCTION; HUMANS; HYDRAZONES; INFLAMMATION; INTERFERON TYPE II; INTERLEUKIN-1; INTERLEUKIN-6; KINETICS; LIPOPOLYSACCHARIDES; MACROPHAGE INFLAMMATORY PROTEIN-1; MACROPHAGES; MICE; MONOCYTES; MONOKINES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 15844399881     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.183.3.927     Document Type: Article

References (27)

1. Parrillo, J.E. 1993. Pathogenetic mechanisms of septic shock. N. Engl. J. Med. 328:1471-1477.
2. Nathan, C. 1992. Nitric oxide as a secretory product of mammalian cells. FASEB (Fed. Am. Soc. Exp. Biol.) J. 6:3051-3064.
3. Cobb, J.P., R.E. Cunnion, and R.L. Danner. 1993. Nitric oxide as a target for therapy in septic shock. Crit. Care Med. 21:1261-1263.
4. Tracey, K.J. 1992. The acute and chronic pathophysiological effects of TNF: mediation of septic shock and wasting (cachexia). In Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine. B. Beutler, editor. Raven Press, Ltd., New York. 255-273.
5. Tracey, K.J., Y. Fong, D.G. Hesse, K.R. Manogue, A.T. Lee, G.C. Kuo, S.F. Lowry, and A. Cerami. 1987. Anticachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature (Lond.). 330:662-664.
6. Gershenwald, J.E., Y. Fong, T.F. Fahey III, S.E. Calvano, R. Chizzonite, P.L. Kilian, S.F. Lowry, and L.L. Moldawer. 1990. Interleukin 1 receptor blockade attenuates the host inflammatory response. Proc. Natl. Acad. Sci. USA. 87:4966-4970.
7. Mohler, K.M., D.S. Torrance, C.A. Smith, R.G. Goodwin, K.E. Stremler, V.P. Fung, H. Manani, and M.B. Widmer. 1993. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. 151:1548-1561.
8. Abraham, E., R. Wunderink, H. Silverman, T.M. Perl, S. Hasraway, H. Levy, R. Bone, R.P. Wenzel, R. Balk, R. Allred, et al. 1995. Efficacy and safety of monoclonal antibody to human tumor necrosis antibody to human tumor necrosis factor α in patients with sepsis syndrome. J. Am. Med. Assoc. 273:934-941.
9. McNamara, M.J., J.A. Norton, R.J. Nauta, and H.R. Alexander. 1993. Interleukin-1 receptor antibody (IL-1rab) protection and treatment against lethal endotoxemia in mice. J. Surg. Res. 54:316-321.
10. Sampaio, E.P., E.N. Sarno, R. Gallily, Z.A. Cohn, and G. Kaplan. 1991. Thalidomide selectively inhibits TNF-α production by stimulated human monocytes. J. Exp. Med. 173: 699-703.
11. Moreira, A.L., E.P. Sampaio, A. Zmuidzinas, P. Frindt, K.A. Smith, and G. Kaplan. 1993. Thalidomide exerts its inhibitory action on TNF-α by enhancing mRNA degradation. J. Exp. Med. 177:1675-1680.
12. Lee, J.C., J.T. Laydon, P.C. McDonnell, T.F. Gallagher, S. Kumar, D. Green, D. McNulty, M.J. Blumenthal, J.R. Heys, S.W. Landvatter, et al. 1995. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature (Lond.). 372:739-746.
13. Baydoun, A.R., R.G. Bogle, J.D. Pearson, and G.E. Mann. 1991. Selective inhibition by dexamethasone of induction of NO synthase, but not of induction of L-arginine transport, in activated murine macrophage J774 cells. Br. J. Pharmacol. 110: 1401-1406.
14. Novogrodsky, A., A. Vanichkin, M. Patya, A. Gazit, N. Osherov, and A. Levitzki. 1994. Prevention of lipopolysaccharide-induced lethal toxicity by tyrosine kinase inhibitors. Science (Wash. DC). 264:1319-1322.
15. Bianchi, M., P. Ullrich, M. Meistrell III, G.A. Zimmerman, H. Schmidtmayerova, M. Bukrinsky, T. Donnelly, R. Bucala, B. Sherry, K.R. Manogue, et al. 1995. An inhibitor of macrophage arginine transport and nitric oxide production (CNI-1493) prevents acute inflammatory and endotoxin lethality. Mol. Med. 3:254-266.
16. Sambrook, J., E.F. Fritsch, and T. Maniatis. 1989. Molecular Cloning: A Laboratory Manual. Book 1. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. 7.12-7.15.
17. Jue, D.-M., B. Sherry, C. Leudke, K.R. Manogue, and A. Cerami. 1990. Processing of newly synthesized cachectin/tumor necrosis factor in endotoxin-stimulated macrophages. Biochemistry. 29:8371-8377.
18. Beutler, B., J. Han, V. Kruys, and B.P. Giroir. 1992. Coordinate regulation of TNF biosynthesis at the levels of transcription and translation - patterns of TNF expression in vivo. In Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine. B. Beutler, editor. Raven Press, New York. 561-574.
19. Tracey, K.J., B. Beutler, S.F. Lowry, J. Merryweather, S. Wolpe, I.W. Milsark, R.J. Hariri, T.F. Fahey III, A. Zentella, J.D. Albert, et al. 1986. Shock and tissue injury induced by recombinant human cachectin. Science (Wash. DC). 234:470-474.
20. Vodovotz, Y., N.S. Kwon, M. Pospischil, J. Manning, J. Paik, and C. Nathan. 1994. Inactivation of nitric oxide synthase after prolonged incubation of mouse macrophage with IFN-gamma and bacterial lipopolysaccharide. J. Immunol. 152:4110-4118.
21. Van Dervort, A.L., L. Yan, P.J. Madara, J.P. Cobb, R.A. Wesley, C.C. Corriveau, M.M. Tropea, and R.L. Danner. 1994. Nitric oxide regulates endotoxin-induced TNF-alpha production by human neutrophils. J. Immunol. 152:4102-4109.
22. Beutler, B., V. Tkacenko, I. Milsark, N. Krochin, and A. Cerami. 1986. Effect of γ interferon on cachectin expression by mononuclear phagocytes. Reversal of the lpsd (endotoxin resistance) phenotype. J. Exp. Med. 164:1791-1796.
23. Leudke, C.E., and A. Cerami. 1990. Interferon-γ overcomes glucocorticoid suppression of cachectin/tumor necrosis factor biosynthesis by murine macrophages. J. Clin. Invest. 86:1234-1240.
24. Trede, N.S., E. Castigli, R.S. Geha, and T. Chatila. 1993. Microbial superantigens induce NF-kappa B in the human monocytic cell line THP-1. J. Immunol. 150:5604-5609.
25. Pfeffer, K., T. Matsuyama, T.M. Kundig, A. Wakeham, K. Kishihara, A. Shahinian, K. Wiegmann, P.S. Ohashi, M. Kronke, and T.W. Mak. 1993. Mice deficient for the 55 kD tumor necrosis factor receptor are resistant to endotoxin shock, yet succumb to L. monocytogenes infection. Cell. 73: 457-467.
26. Titus, R.G., B. Sherry, and A. Cerami. 1989. Tumor necrosis factor plays a protective role in experimental murine cutaneous Leishmaniasis. J. Exp. Med. 170:2097-2104.
27. Hansen, M.B., S.E. Nielsen, and K. Berg. 1989. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods. 119:203-206.